Showing 1 - 3 results of 3 for search 'Yoo‐Joung Ko', query time: 0.03s Refine Results
  1. 1
    Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab

    Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, a... by Andrea S. Fung, Vincent C. Tam, Daniel E. Meyers, Hao‐Wen Sim, Jennifer J. Knox, Valeriya Zaborska, Janine Davies, Yoo‐Joung Ko, Eugene Batuyong, Haider Samawi, Winson Y. Cheung, Richard Lee‐Ying

    Published 2020-07-01
    Get full text
    Article
  2. 2
    Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database

    Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database by Haider H. Samawi, Hao‐Wen Sim, Kelvin K. Chan, Mohammad A. Alghamdi, Richard M. Lee‐Ying, Jennifer J. Knox, Parneet Gill, Adriana Romagnino, Eugene Batuyong, Yoo‐Joung Ko, Janine M. Davies, Howard J. Lim, Winson Y. Cheung, Vincent C. Tam, the CHORD Consortium

    Published 2018-07-01
    Get full text
    Article
  3. 3
    Pan-Canadian consensus recommendations for GIST management in high- and low-throughput centres across Canada

    Pan-Canadian consensus recommendations for GIST management in high- and low-throughput centres across Canada by J. Robert Beecroft, Savtaj Brar, Xiaolan Feng, Trevor Hamilton, Cheng Han-Lee, Jan-Willem Henning, P. David Josephy, Korosh Khalili, Yoo-Joung Ko, Christopher Lemieux, David M. Liu, D. Blair MacDonald, Jonathan Noujaim, Aaron Pollett, Abdulazeez Salawu, Ramy Saleh, Alannah Smrke, Blair E. Warren, Kevin Zbuk, Albiruni Abdul Razak

    Published 2024-07-01
    Get full text
    Article

Search Tools: